Electronic Supplementary Information (ESI)

Characterization of Mammalian N-degrons and Development of Heterovalent Inhibitors of the N-end Rule Pathway

Yanxialei Jiang,^{†1} Subrata Kumar Pore,^{†2} Jung Hoon Lee,¹ Shashi Sriram,³ Binh Khan Mai,¹ Dong Hoon Han,¹ Pritha Agarwalla,² Adriana Zakrzewska,³ Yongho Kim,¹ Rajkumar Banerjee,^{*2} Seung-Han Lee,¹ and Min Jae Lee^{*1}

¹Department of Applied Chemistry, College of Applied Sciences, Kyung Hee University, Yongin 446-701, Korea.

²Division of Lipid Science and Technology, CSIR-Indian Institute of Chemical Technology, Hyderabad, Andhra Pradesh 500007, India.

³Center for Pharmacogenetics and Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.

TABLE OF CONTENTS

ESI METHODS	p. S2
ESI SYNTHESIS SCHEMES AND CHARACTERIZATIONS	p. S5
ESI References	p. S31
ESI FIGURES AND FIGURE LEGENDS	p. S33

ESI Methods

In vitro degradation/ubiquitination assay.

Time- and concentration-dependent *in vitro* degradation assays were performed as described.¹ Briefly, biotinylated lysine-tRNA complex (Transcend tRNA, Promega) was added to a reaction mixture to randomly label DHFR-Ub-X-nsP4 fusion protein with biotin. The nonstructural protein 4 (nsP4) of Sindbis virus originally bears N-terminal Tyr and it is degraded by the N-end rule pathway^{2,3}. The N-terminal residue of nsP4 is mutagenated to various amino acids (X-nsP4) to generate N-end rule substrates and controls. Biotinylated proteins were detected with horseradish peroxidase (HRP)-conjugated streptavidin (Pierce). For quantitative immunoblotting, proteins were visualized by infrared fluorescence using the and IR dye-conjugated streptavidin (Li-COR). For Odyssey Imaging System autoradiographic assay, ³⁵S-methionine (Amersham Bioscience) and supplements were added to the *in vitro* transcription/translation reaction. To produce the DHFR-Ub-X-nsP4 plasmids, X-nsP4 was amplified by PCR and subcloned into the UPR vector pcDNA3(dEheI)FDHUMCM using SmaI/XbaI cut. Ubiquitination of test proteins was characterized in the presence of 5 µM MG132, followed by anti-Ub immunoprecipitation and anti-biotin Western blotting

Mammalian Cell Culture and transient expression.

HeLa cells were grown in DMEM supplemented with 10 % FBS, 2 mM glutamine, and 100 units/ml penicillin/streptomycin. Cells were transfected with 2-4 μ g of plasmid DNA expressing X-GFP in a 6-well culture plate for 4 hr using LipofectAMINE 2000 (Invitrogen) when cells were >95% confluent or at a density of 10⁶ cells/well. Cell lysates were prepared 36-48 hr post-transfection in RIPA buffer and used for immunoblotting. In a given panel, each lane is loaded with extract from an equal cell number, generally corresponding to 10-20 μ g/lane, or 1/10 of the sample recovered from one well of a 6-well plate.

Expression of N-end rule model substrates in mammalian cells.

Mammalian cells, such as MEF and cardiac cells, were transiently transfected with $2 \sim 4 \mu g$ of

total plasmid DNA in a 6-well plate for 4~6 hr using Lipofectamine2000 (Invitrogen) when cells were >95% confluent. Cell lysates were collected ~36 hr post-transfection in RIPA buffer and used for immunoblotting or immunoprecipitation. The level of total ubiquitinated Arg-GFP was detect in the presence of 10 μ M MG132. For pulse-chase analysis, cells were labeled with ³⁵S -methionine/cysteine (³⁵S-Express protein labeling mix; Perkin-Elmer) after 24 hr of transfection, followed by a cycloheximide chase. Whole cell extracts were prepared and immunoprecipitated, followed by SDS-PAGE and autoradiography, as previously described.^{4,5}

In silico docking analysis of protein-protein and protein-ligand interactions.

Crystal structures of UBR1, UBR2, and ClpS boxes were taken from the Protein Data Bank (PDB ID: 3NY1, 3NY3, and 3DNJ, respectively). Because the "combined" UBR2-ClpS structure is unknown, the Gramm-X protein-protein docking web server⁶ was used to dock the UBR2 and ClpS boxes. Two possible UBR2-ClpS structures were found with most stable binding energies. The RIFS and YLFV peptide structures were extracted from their complexes with the UBR2 box and ClpS, respectively. Other peptides were created with the Mutagenesis module in the PyMOL package (http://sourceforge.net/projects/pymol/). The RF-C5 structure was optimized using the semi-empirical PM6 method⁷ with the Gaussian 09 program.⁸

AutoDockTools⁹ version 1.5.4 was used to add polar hydrogens and assign Gasteiger charges¹⁰ to proteins, peptides, and RF-C5. For each protein, AutoGrid version 4.2 was used to create affinity grids centered on the active site. The grids were large enough to contain all the active sites. AutoDock version 4.2 with the Lamarckian genetic algorithm was used to simulate ligand-receptor docking.¹¹ Docking parameters were as follows: trials of 200 dockings, population size of 300, random starting position and conformation, translation step ranges of 2.0 Å, rotation step ranges of 50°, elitism of 1, mutation rate of 0.02, cross over rate of 0.8, local search rate of 0.06, and 50 million energy evaluations. Docked conformations were clustered using a tolerance of 2.0 Å RMSD. The lowest binding energy of the most populated cluster was compared to experimental data. Experimental binding free energies were calculated from dissociation constants based on the equation: $\Delta G = RT \ln K_d$, where R is gas constant (1.987 cal K⁻¹ mol⁻¹) and T is temperature (298.15 K). The PBD2PQR web server¹² was used to create a PQR file at pH=7 and AMBER force field.¹³ Electrostatic

potentials were calculated using APBS package.¹⁴ All structural figures were prepared using the PyMOL package.

Assessment of cell viability.

Cell viability was assessed using a modified MTT assay.¹⁵ RF-C11 and GV-C11 in DMSO were added at various concentrations (0.1 μ M to 1000 μ M) to cells. After incubating for 4 h, 25 μ L of 5 mg/mL MTT solution was added to the samples and the plates were incubated for 2 h at 37°C. Thiazolyl blue tetrazolium bromide (MTT, Sigma Aldrich) was added to each well (final concentration 0.5 mg/mL) and incubated for 2 h at 37°C in a humidified atmosphere of 95% air and 5% CO₂. HCl (0.08 N) in isopropanol was added to solubilize the blue MTT-formazan product and the cells were incubated for 30 min at room temperature. The absorbance of the solution was read at 570 nm (test) and 630 nm (reference).

ESI Synthesis Schemes and Characterization of RF-Cn Series and Their Derivatives

Overview

Protected amino acids were purchased from Novabiochem. Organic solvents were purchased from Ranbaxy Fine Chemicals, and other chemicals were from Sigma-Aldrich. ¹H NMR spectra were recorded on Varian FT 200 MHz, or Bruker FT 300 MHz. Mass spectra were obtained by Micromass Quattro LC (ESI). Analytical TLC was performed with silica gelcoated aluminum plates (Merck). Purity of final products was determined by using Varian Prostar HPLC with Prostr 325 UV-Vis detector at a flow rate of 1 ml/min in Hibar Purospher





18g: FF-C5 where R₅= -CH₂-C₆H₅

Scheme3: Synthetic scheme of compound RR-C5 and FF-C5

STAR column (4.6 mm-250 mm, RP-18e) (Merck). DCM (dichloromethane), DIPEA (diisopropylethylamine), DMF (dimethylformamide), DMSO (dimethyl sulfoxide), EDCI (N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride), HOBt (1-hydroxy-1H-benzotriazole hydrate), r.t. (room temperature), TFA (trifluoroacetic acid), THF (tetrahydrofuran), TMS-OTf (trimethylsilyl trifluoromethanesulfonate).

Scheme4: Synthetic scheme of compound biotinylated-RF-C5 (RF-C5b)

Synthesis of compound RF-C2 and RF-C3

Synthesis of N(ɛ)-Z-Lysine(-OMe)C2-NHBoc, 1a

HOBt (0.463g, 3.02mmol) and EDCI (0.579g, 3.02mmol) were sequentially added to an icecold stirred solution of Boc-Gly-OH (0.529g, 3.02mmol) in dry DCM. After half an hour N(ϵ)-Z-lysine methyl ester hydrochloride (1g, 3.02mmol) dissolved in dry DCM was added to the reaction mixture. Then DIPEA was added drop wise till the reaction mixture became slightly basic. The resulting solution was stirred at r.t. overnight. Then it was diluted with DCM and washed sequentially with 1N HCl, water and brine. The organic layer was dried and evaporated. The residue was purified by column chromatography using 1% methanol in chloroform. The yield of pure N(ϵ)-Z-Lysine(-OMe)C2-NHBoc was 92.2% and it was faint yellowish gummy compound. (R_f = 0.55 in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃): δ = 1.2-1.5 [m, 13H], 1.75-1.9 [m, 2H], 3.1-3.3 [m, 2H], 3.65-3.8 [m, 5H], 4.4-4.6 [q, 1H], 5.05-5.1 [s, 2H], 5.1-5.3 [m, 1H], 5.35-5.5 [m, 1H], 6.9-7.1[d, 1H], 7.2-7.5[s, 5H]. ESI-MS: m/z = 452.7 (calculated value for C₂₂H₃₃O₇N₃ =451.5).

Synthesis of N(ε)-Z-Lysine(-OMe)C3-NHBoc, 1b

Yield: 86.7% ($R_f = 0.55$ in 5% methanol in chloroform). ¹**H** NMR (300MHz, CDCl₃): $\delta = 1.4-1.7$ [m, 13H], 1.75-1.9 [m, 2H], 2.3-2.45 [m, 2H], 3.1-3.2 [m, 2H], 3.25-3.4 [m, 2H], 3.7 [s, 3H], 4.45-4.55 [m, 1H], 5.0-5.1 [s, 2H], 5.2-5.3 [m, 1H], 6.5-6.6 [m, 1H], 7.25-7.35[m, 6H]. **ESI-MS**: m/z = 489.0 [M+Na⁺] (calculated value for C₂₃H₃₅O₇N₃ = 465.5).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C2-NH₂, 2a

TFA was added slowly to a solution of N(ε)-Z-Lysine(-OMe)C2-NHBoc (1.2g, 2.66mmol) in dry DCM at 0^oC and the mixture was allowed to stir for 3 hours at r.t. Then DCM and excess TFA were removed by nitrogen flushing. The gummy residue upon chromatographic purification using 2% methanol in chloroform gave 0.84g (90% yield) of pure N(ε)-Z-Lysine(-OMe)C2-NH₂ as a yellowish solid. (R_f = 0.1 in 5% methanol in chloroform). **ESI-MS**: m/z = 352.7 (calculated value for C₁₇H₂₅O₅N₃=351.4).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C3-NH₂, 2b

Yield: 90% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 366 (calculated value for $C_{18}H_{27}O_5N_3 = 365.4$).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C2F, 3a

HOBt (0.29g, 1.91mmol) and EDCI (0.37g, 1.91mmol) were sequentially added to an icecold stirred solution of Boc-Phe-OH (0.51g, 1.91mmol) in dry DCM. After half an hour N(ε)-Z-Lysine(-OMe)C2-NH₂ (0.84g, 2.39mmol) dissolved in dry DCM was added to the reaction mixture. Then DIPEA was added drop wise till the reaction mixture became slightly basic. The resulting solution was stirred at r.t. overnight. Then it was diluted with DCM and washed sequentially with 1N HCl, water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 2% methanol in chloroform gave 1.079g (75.5% yield) of pure N(ε)-Z-Lysine(-OMe)C2F as a faint yellowish liquid. (R_f = 0.5 in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃): δ = 1.2-1.6 [m, 11H], 1.6-1.9 [m, 4H], 2.8-3.0 [m, 2H], 3.05-3.15 [m, 2H], 3.6 [s, 3H], 3.8-4.0 [m, 1H], 4.15-4.35 [m, 2H], 4.4-4.6 [m, 1H], 5.05 [s, 2H], 5.2-5.3 [m, 1H], 5.4-5.55 [d, 1H], 6.9-7.4 [m, 12H]. ESI-MS: m/z = 622 [M+Na⁺] (calculated value for C₃₁H₄₂O₈N₄ = 598.7).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C3F, 3b

Yield: 64.9% ($R_f = 0.5$ in 5% methanol in chloroform). ¹**H NMR** (300MHz, CDCl₃): $\delta = 1.2$ -1.6 [m, 15H], 1.6-1.9 [m, 2H], 2.15-2.45 [m, 2H], 2.8-3.25 [m, 4H], 3.7-3.8 [s, 3H], 4.15-4.25 [q, 1H], 4.4-4.5 [q, 1H], 4.9-5.0 [m, 1H], 5.15 [s, 2H], 5.2 [m, 1H], 6.95-7.1 [m, 1H], 7.1-7.4 [m, 11H]. **ESI-MS**: m/z = 635 [M+Na⁺] (calculated value for $C_{32}H_{44}O_8N_4 = 612.7$).

Synthesis of Lysine(-OMe)C2F, 4a

N(ε)-Z-Lysine(-OMe)C2F (1g, 1.67mmol) was dissolved in HPLC grade methanol (15ml). The air of the container was chased by flushing nitrogen several times. 10% Pd on charcoal (0.4g) was added cautiously to the solution and inner walls of the flask were washed down with HPLC grade methanol. Again the air of the flask was chased by nitrogen flushing. Then hydrogen gas was passed through the reaction mixture and it was left stirring for overnight. Then it was filtered through celite and washed with HPLC grade methanol. The combined washings along with the filtrate was evaporated to get 0.816g (90%) of Lysine(-OMe)C2F as a white semi solid. This was used directly in the next reaction without further purification. (R_f = 0.1 in 5% methanol in chloroform). **ESI-MS**: m/z = 465.9 (calculated value for C₂₃H₃₆O₆N₄ = 464.6).

Synthesis of Lysine(-OMe)C3F, 4b

Yield: 95.3% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 480.0 (calculated value for $C_{24}H_{38}O_6N_4 = 478.6$).

Synthesis of Lysine(-OMe)C2FC2-NHZ, 5a

HOBt (0.183g, 1.2mmol) and EDCI (3.5g, 1.2mmol) were sequentially added to an ice-cold stirred solution of Z-Gly-OH (0.25g, 1.2mmol) in dry DCM. After half an hour Lysine(-OMe)C2F (0.695g, 1.5mmol) dissolved in dry DCM was added to the reaction mixture. Then DIPEA was added drop wise till the reaction mixture became slightly basic. The resulting solution was stirred at r.t. overnight. Then it was diluted with DCM and washed sequentially with 1N HCl, water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 1.5% methanol in chloroform gave 0.69g (70.3% yield) of pure N(ε)-Z-Lysine(-OMe)C2FC2-NHZ as a yellowish semi-solid. (R_f = 0.3 in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃): δ = 1.2-1.55 [m, 11H], 1.75-1.9 [m, 4H], 2.8-3.5 [m, 4H], 3.6 [m, 5H], 3.6-3.8 [m, 2H], 4.2-4.3 [m, 1H], 4.45-4.6 [m, 1H], 5.1 [s, 2H], 5.65-5.75 [m, 1H], 6.2-6.3 [m, 1H], 6.9-7.0 [m, 1H], 7.1-7.4 [m, 12H]. ESI-MS: m/z = 656.9 [M+H⁺], & 679.1[M+Na⁺] (calculated value for C₃₃H₄₅O₉N₅ = 655.7).

Synthesis of Lysine(-OMe)C3FC3-NHZ, 5b

Yield: 56.8% ($R_f = 0.3$ in 5% methanol in chloroform). ¹**H NMR** (200MHz, CDCl₃): $\delta = 1.2$ -1.9 [m, 15H], 2.25-2.55 [m, 4H], 2.8-3.5 [m, 8H], 3.7 [s, 3H], 4.2-4.3 [m, 1H], 4.35-4.5 [m, 1H], 5.0-5.1 [s, 2H], 5.2-5.35 [m, 1H], 7.1-7.4 [m, 10H]. **ESI-MS**: m/z = 685.3 (calculated value for $C_{35}H_{49}O_9N_5 = 683.8$).

Synthesis of Lysine(-OMe)C2FC2-NH₂, 6a

 $N(\epsilon)$ -Z-Lysine(-OMe)C2FC2-NHZ (0.69g, 1.05mmol) was dissolved in HPLC grade THF (15ml). The air of the container was chased by flushing nitrogen several times. 10% Pd on charcoal (0.4g) was added cautiously to the solution and inner walls of the flask were washed down with HPLC grade THF. Again the air of the flask was chased by nitrogen flushing. Then hydrogen was passed through the reaction mixture and it was left stirring for overnight. Then it was filtered through celite and washed with HPLC grade THF. The combined washings along with the filtrate was evaporated to afford 0.49g (90%) of Lysine(-OMe)C2FC2-NH₂ as a white semi solid. This was used directly in the next reaction without further purification. ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 522.8 (calculated value for $C_{25}H_{39}O_7N_5 = 521.6$).

1.4.2.12 Synthesis of Lysine(-OMe)C3FC3-NH₂, 6b

Yield: 90% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 551 (calculated value for $C_{27}H_{43}O_7N_5 = 549.7$).

Synthesis of PRF-C2, 7a

HOBt (0.112 g, 0.74mmol) and EDCI (0.141g, 0.74mmol) were sequentially added to an icecold stirred solution of Z-Arg-(Z)₂-OH (0.424g , 0.74mmol) in dry DCM. After half an hour Lysine(-OMe)C2F2-NH₂ (0.48g, 0.92mmol) dissolved in dry DMF was added to the reaction mixture. Then DIPEA was added dropwise till the reaction mixture became slightly basic. The resulting solution was stirred at r.t. overnight. Then it was diluted with DCM and washed sequentially with 1N HCl, water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 1.5% methanol in chloroform afforded 0.558g (56.1% yield) of pure PRF-C2 as a white gummy semi-solid. ($R_f = 0.4$ in 5% methanol in chloroform). ¹H NMR (300MHz, CDCl₃ + CD₃OD): $\delta = 1.4-2.2$ [m, 19H], 3.0-3.5 [m, 4H], 3.9 [s, 3H], 4.0-4.4 [m, 7H], 4.4-4.7 [m, 2H], 5.2-5.5 [m, 6H], 6.8-7.2 [m, 3H], 7.3-7.6 [m, 20H], 9.9 [s, 1H]. ESI-MS: m/z = 1082 [M+H⁺] & 1104 [M+Na⁺] (calculated value for C₅₅H₆₉O₁₄N₉ = 1080.8).

Synthesis of PRF-C3, 7b

Yield: 64.6% ($R_f = 0.4$ in 5% methanol in chloroform). ¹**H NMR** (300MHz, CDCl₃): $\delta = 1.2$ -1.5 [m, 15H], 1.6-1.8 [m, 4H], 2.3-2.65 [m, 8H], 3.1-3.25 [m, 2H], 3.4-3.6 [m, 4H], 3.7 [s, 3H], 4.05-4.2 [m, 1H], 4.2-4.4 [m, 2H], 5.0-5.4 [m, 6H], 7.15-7.45 [m, 20H].**ESI-MS**: m/z = 1108 (calculated value for $C_{57}H_{73}O_{14}N_9 = 1108.2$).

Synthesis of RF-C2, 8a

PRF-C2 (0.1g, 0.093mmol) was dissolved in TFA (2ml) under nitrogen atmosphere and kept stirred in an ice bath. Thioanisole (0.4ml, 3.4mmol) and TMSOTf (0.6ml, 3.32mmol) were added sequentially to that cooled solution. The reaction mixture was allowed to come to r.t. and stirring was continued for 24 hours. Then reaction was quenched with HPLC grade methanol. Methanol and excess TFA were chased by nitrogen flushing. The residue reprecipitated from methanol-acetone system repeatedly. Finally, upon chloride ion exchange chromatography (using amberlite IRA-400Cl chloride ion exchange resin) gave 0.031g (57% yield) of pure RF-C2 as a yellowish white semi-solid. ($R_f = 0.1$ in 20% methanol in chloroform). **ESI-HRMS**: m/z = 578.3391 ([M+H]⁺, calculated value for C₂₆H₄₄O₆N₉ = 578.3414). RP-HPLC: Rt = 3.9 min (20% water in acetonitrile), purity >99%.

Synthesis of RF-C3, 8b

Yield: 61.6% ($R_f = 0.1$ in 20% methanol in chloroform). **ESI-HRMS**: m/z = 606.3728 ($[M+H]^+$, calculated value for $C_{28}H_{48}O_6N_9 = 606.3727$). RP-HPLC: Rt = 2.9 min (20% water in acetonitrile), purity >99%.

Synthesis of compound RF-C5, RF-C8, RF-C9, RF-C15, GV-C5, RR-C5 and FF-C5 Synthesis of *tert*-butyl-5-bromopentanoate, 9a

N, N'-dimethylaminopyridine (1.68g, 13.75mmol) and DCC (6.83g, 33.15mmol) were added sequentially to an ice-cold stirred solution of 5-bromopentanoic acid (5g, 27.62mmol) in dry DCM. After half an hour *tert*-butanol (15.8ml, 165.75mmol) was added to the reaction mixture. The resulting solution was stirred at r.t. overnight. Then it was diluted with DCM and washed sequentially with water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 1% ethyl acetate in hexane afforded 4.1g (62.6% yield) of pure *tert*-butyl-5-bromopentanoate as a light yellow liquid. ($R_f = 0.8$ in 20% ethyl acetate in hexane). ¹H NMR (200MHz, CDCl₃): $\delta = 1.44$ [s, 9H], 1.5-1.6 [m, 2H], 1.84-1.96 [m, 2H], 2.24 [t, 2H], 3.4 [t, 2H]. ESI-MS: m/z = 258 (calculated value for C₉H₁₇O₂Br = 237.1).

Synthesis of tert-butyl-8-bromooctanoate, 9b

Yield: 70.5% ($R_f = 0.85$ in 20% ethyl acetate in hexane). ¹**H NMR** (300MHz, CDCl₃): $\delta = 1.28-1.36$ [m, 6H], 1.4-1.48 [s, 9H], 1.55-1.64 [m, 2H], 1.8-1.92 [q, 2H], 2.16-2.24 [t, 2H], 3.36-3.44 [t, 2H].

Synthesis of tert-butyl-15-bromopentadecanoate, 9c

Yield: 75% ($R_f = 0.9$ in 20% ethyl acetate in hexane). ¹**H NMR** (300MHz, CDCl₃): $\delta = 1.2$ -1.36 [m, 20H], 1.36-1.44 [m, 9H], 1.48-1.6 [m, 2H], 1.8-1.92 [q, 2H], 2.12-2.2 [t, 2H], 3.32-3.4 [t, 2H].

Synthesis of tert-butyl-5-aminopentanoate, 10a

tert-butyl-5-bromopentanoate (3.6g , 15.19mmol) was dissolved in dry DMF (10ml) and sodium azide (1.48g , 22.77mmol) was added into it. The reaction mixture was heated to 70- 80^{0} C and stirred for 17-18 hours. Then it was allowed to cool to r.t. It was diluted with chloroform and sequentially washed with water and brine. The chloroform layer was dried and evaporated. Triphenylphosphine (2.29g, 8.77mmol) was added to the gummy crude material. A vigorous evolution of nitrogen was observed and THF was added to it. When evolution of nitrogen ceased, few drops of water was added to the reaction mixture and stirring was continued for further 4 hours. Then THF was evaporated. The residue upon chromatographic purification using 5% methanol in chloroform afforded 2.79g (96% yield) of pure *tert*-butyl-5-aminopentanoate as a yellow liquid. (R_f = 0.1 in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃): δ = 1.28 [s, 12 H], 1.44 [s, 9H], 1.5-1.6 [m, 4H], 2.1-2.2 [t, 2H], 2.76-2.84 [t, 2H], 2.92-3.4 [m, 2H].

Synthesis of tert-butyl-8-aminooctanoate, 10b

Yield: 90.5% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 216.5 (calculated value for $C_{12}H_{25}O_2N = 215.3$).

Synthesis of tert-butyl-9-aminononanoate, 10c

tert-butyl-8-bromooctanoate (1.87g, 6.71mmol) was dissolved in dry DMSO (3ml) and sodium cyanide (2.63g, 53.68mmol) was added. Sodium iodide was added in catalytic amount. The reaction mixture was heated to $80-90^{\circ}$ C and stirred for 2-3 hours. Then it was

allowed to cool to r.t. It was diluted with chloroform and sequentially washed with cold water and brine. The organic layer was dried and evaporated. The crude material was dissolved in ice cold dry MeOH and anhydrous nickel chloride (0.081g, 0.625mmol) was added. After some time sodium borohydride (1.65g, 43.54mmol) was added to reaction mixture and left for 2-3 hours. Then reaction mixture was filtered through celite and washed with HPLC grade MeOH. MeOH was driven out and crude was dissolved in chloroform. Work up was done with brine water and dried. The residue upon chromatographic purification using 5% methanol in chloroform afforded 1.26g (88.6% yield) of pure *tert*-butyl-9-aminononanoate as a yellow liquid. ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 230 (calculated value for C₁₃H₂₇O₂N = 229.4).

Synthesis of tert-butyl-15-aminopentadecanoate, 10d

Yield: 85% ($R_f = 0.1$ in 5% methanol in chloroform).

Synthesis of RC5(-CO₂Bu^t), 11a

HOBt (0.35g, 2.31mmol) and EDCI (0.44g, 2.30mmol) were sequentially added to an icecold stirred solution of Z-Arg-(Z)₂-OH (1.54g, 2.82mmol) in dry DCM. After half an hour *tert*-butyl-5-aminopentanoate (0.50 g, 2.89mmol) dissolved in dry DCM was added to the reaction mixture. DIPEA was added drop wise to make reaction mixture slightly basic. The resulting solution was stirred at r.t. overnight. Then it was diluted with chloroform and washed sequentially with water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 1% methanol in chloroform afforded 1.73g (72% yield) of pure RC5(-CO₂Bu^t) as a white solid. (R_f = 0.8 in 5% methanol in chloroform). ¹**H NMR** (200MHz, CDCl₃): δ = 1.1-1.2 [m, 2H], 1.4 [s, 9H], 1.5-1.8 [m, 6H], 2.1 [t, 2H], 2.7-2.9 [m, 2H], 3.7-3.8 [m, 2H], 4.2-4.4 [m, 1H], 4.9-5.1 [m, 6H], 6.2 [d, 1H], 6.5-6.6 [t, 1H], 7.2-7.4 [m, 15H], 9.3-9.5 [m, 2H]. **ESI-MS**: m/z = 732 (calculated value for C₃₉H₄₉O₉N₅ = 731.8).

Synthesis of RC8(-CO₂Bu^t), 11b

Yield: 65.2% ($R_f = 0.85$ in 5% methanol in chloroform). ¹**H** NMR (300MHz, CDCl₃+CD₃OD): $\delta = 1.1-1.35$ [m, 10H], 1.45 [s, 9H], 1.5-1.7 [m, 4H], 2.1-2.25 [t, 2H], 2.9-3.1 [t, 2H], 3.8-4.1 [m, 3H, (merged with solvent peak)], 5.05-5.25 [m, 6H], 7.25-7.4 [m, 15H]. **ESI-MS**: m/z = 775 (calculated value for C₄₂H₅₅O₉N₅ = 773.9).

Synthesis of RC9(-CO₂Bu^t), 11c

Yield: 60.5% ($R_f = 0.85$ in 5% methanol in chloroform). ¹H NMR (300MHz, CDCl₃): $\delta = 1.1-1.8$ [m, 25H], 2.15-2.25 [m, 4H], 2.3-2.4 [t, 2H], 5.05-5.3 [m, 6H], 7.2-7.4 [m, 15H]. **ESI-MS**: m/z = 789 (calculated value for C₄₃H₅₇O₉N₅ = 787.9).

Synthesis of RC15(-CO₂Bu^t), 11d

Yield: 67.5% ($R_f = 0.9$ in 5% methanol in chloroform).

Synthesis of GC5(-CO₂Bu^t), 11e

Yield: 63.1% ($R_f = 0.6$ in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃): $\delta = 1.4$ [s, 9H], 1.5-1.6 [m, 4H], 2.2 [t, 2H], 3.2 [m, 2H], 3.8 [d, 2H], 5.1 [s, 2H], 5.55 [m, 1H], 6.35 [m, 1H], 7.25-7.35 [m, 5H]. **ESI-MS**: m/z = 365 (calculated value for $C_{19}H_{28}O_5N_2 = 364.4$).

Synthesis of FC5(-CO₂Bu^t), 11f

Yield: 58.9% ($R_f = 0.7$ in 5% methanol in chloroform). ¹**H NMR** (300MHz, CDCl₃): $\delta = 1.3$ -1.5 [m, 13H], 2.1-2.2 [t, 2H], 2.9-3.2 [m, 4H], 4.3 [m, 1H], 5.05 [s, 2H], 5.45 [d, 1H], 5.85 [t, 1H], 7.1-7.35 [m, 10H]. **ESI-MS**: m/z = 455 (calculated value for $C_{26}H_{34}O_5N_2 = 454.6$).

Synthesis of RC5(-CO₂H), 12a

TFA was added slowly to a solution of RC5(-CO₂Bu^t) (0.95g, 1.3mmol) in dry DCM at 0⁰C and the mixture was allowed to stir for 4 hours at r.t. Then DCM and excess TFA were removed by nitrogen flushing. The gummy residue upon chromatographic purification using 2% methanol in chloroform afforded 0.68g (77.5% yield) of pure RC5(-CO₂H) as a white solid. (R_f = 0.5 in 5% methanol in chloroform). **ESI-MS**: m/z = 676 (calculated value for $C_{35}H_{41}O_9N_5 = 675.7$).

Synthesis of RC8(-CO₂H), 12b

Yield: 81.1% ($R_f = 0.5$ in 5% methanol in chloroform). ¹**H NMR** (200MHz, CDCl₃+CD₃OD): $\delta = 1.15$ -1.4 [m, 10H], 1.5-1.75 [m, 4H], 2.2-2.35 [t, 2H], 2.9-3.1 [m, 2H], 3.35 [m, 2H], 4.1-4.2 [m, 1H], 5.0-5.25 [m, 6H], 7.3-7.5 [m, 15H]. **ESI-MS**: m/z = 718 (calculated value for $C_{38}H_{47}O_9N_5 = 717.8$).

Synthesis of RC9(-CO₂H), 12c

Yield: 75.5% ($R_f = 0.5$ in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃+CD₃OD): $\delta = 1.1-1.4$ [m, 12H], 1.5-1.7 [m, 4H], 2.2-2.3 [t, 2H], 2.9-3.0 [t, 2H], 3.8-4.0 [m, 2H], 4.05-4.1 [m 1H] 5.0-5.25 [m, 6H], 7.2-7.4 [m, 15H]. **ESI-MS**: m/z = 732 (calculated value for $C_{39}H_{49}O_9N_5 = 731.8$).

Synthesis of RC15(-CO₂H), 12d

Yield: 79% ($R_f = 0.6$ in 5% methanol in chloroform).

Synthesis of GC5(-CO₂H), 12e

Yield: 79% ($R_f = 0.4$ in 5% methanol in chloroform). **ESI-MS**: m/z = 309 (calculated value for $C_{15}H_{20}O_5N_2 = 308.3$).

Synthesis of FC5(-CO₂H), 12f

Yield: 84.4% ($R_f = 0.5$ in 5% methanol in chloroform). **ESI-MS**: m/z = 399 (calculated value for $C_{22}H_{26}O_5N_2 = 398.5$).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C5-Br, 13a

HOBt (0.74g, 4.82mmol) and EDCI (1.15g, 6.02mmol) were sequentially added to an icecold stirred solution of 5-bromovaleric acid (1.09g, 6.03mmol) in dry DCM. After half an hour N(ε)-Z-lysine methyl ester hydrochloride (2g, 6.04mmol) dissolved in dry DCM was added to the reaction mixture. Then DIPEA was added drop wise till the reaction mixture became slightly basic. The reaction mixture was stirred at r.t. overnight. Then it was diluted with chloroform and washed sequentially with 0.5N HCl, water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 1% methanol in chloroform afforded 1.83g (66% yield) of pure N(ε)-Z-Lysine(-OMe)C5-Br as a white solid. (R_f = 0.6 in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃): δ = 1.25-1.4 [m, 2H], 1.45-1.6 [m, 2H], 1.65-1.9 [m, 6H], 2.25 [t, 2H], 3.2-3.3 [m, 2H], 3.35 [t, 2H], 3.65 [s, 3H], 4.55 [m, 1H], 4.95 [t, 1H], 5.1 [s, 2H], 6.3 [d, 1H], 7.3 [s, 5H]. ESI-MS: m/z = 458 (calculated value for C₂₀H₂₉O₅N₂Br = 457.4).

Synthesis of N(ε)-Z-Lysine(-OMe)C8-Br, 13b

Yield: 64.85% ($R_f = 0.7$ in 5% methanol in chloroform). ¹H NMR (300MHz, CDCl₃): $\delta = 1.3-1.8$ [m, 14H], 1.8-1.9 [m, 2H], 2.15-2.25 [t, 2H], 3.15-3.25 [m, 2H], 3.35-3.4 [t, 2H], 3.75 [s, 3H], 4.55-4.65 [m, 1H], 4.8-4.9 [t, 1H], 5.1 [s, 2H], 6.1 [d, 1H], 7.25-7.4 [s, 5H]. **ESI-MS**: m/z = 501 (calculated value for C₂₃H₃₅O₅N₂Br = 499.4).

Synthesis of N(ε)-Z-Lysine(-OMe)C15-Br, 13c

Yield: 60.1% ($R_f = 0.75$ in 5% methanol in chloroform). ¹**H** NMR (300MHz, CDCl₃): $\delta = 1.2$ -1.7 [m, 26H], 1.7-1.9 [m, 2H], 2.1-2.2 [t, 2H], 3.1-3.2 [q, 2H], 3.3-3.4 [t, 2H], 3.7 [s, 3H], 4.5-4.6 [m, 1H], 4.75-4.85 [m, 1H], 5.05 [s, 2H], 6..0-6.1 [m, 1H], 7.25-7.35 [s, 5H].

Synthesis of N(ε)-Z-Lysine(-OMe)C5-NH₂, 14a

 $N(\epsilon)$ -Z-Lysine(-OMe)C5-Br (1.5g , 3.28mmol) was dissolved in dry DMF and sodium azide (0.26g, 3.94mmol) was added. The reaction mixture was heated to 70-80^oC and stirred for 17-18 hours. Then it was allowed to cool to r.t. It was diluted with chloroform and sequentially washed with water and brine. The organic layer was dried and evaporated. Triphenylphosphine (1.29g, 4.92mmol) was added to the gummy crude material. A vigorous evolution of nitrogen was observed and THF was added to it. When evolution of nitrogen ceased, few drops of water was added to the reaction mixture and stirring was continued for further 4 hours. Then THF was evaporated in a rotary evaporator. The residue upon chromatographic purification using 5% methanol in chloroform afforded 1.2g (94% yield) of pure N(ϵ)-Z-Lysine(-OMe)C5-NH₂ as a yellowish gummy liquid compound. ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 394 (calculated value for C₂₀H₃₁O₅N₃ = 393.5).

Synthesis of N(ε)-Z-Lysine(-OMe)C8-NH₂, 14b

Yield: 88.5% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 436.8 (calculated value for $C_{23}H_{37}O_5N_3 = 435.6$).

Synthesis of N(ε)-Z-Lysine(-OMe)C9-NH₂, 14c

 $N(\varepsilon)$ -Z-Lysine(-OMe)C8-Br (1.23g, 2.46mmol) was dissolved in dry DMSO and sodium cyanide (0.97g, 19.72mmol) was added. Sodium iodide was added in catalytic amount. The reaction mixture was heated to 80-90^oC and stirred for 2-3 hours. Then it was allowed to cool to r.t. It was diluted with chloroform and sequentially washed with cold water and brine. The organic layer was dried and evaporated. A reddish yellow product was observed. The crude

material was dissolved in ice cold dry MeOH and anhydrous nickel chloride (0.24g, 1.88mmol) was added. After some time sodium borohydride (0.5g, 13.15mmol) was added to reaction mixture and left for 2-3 hours. Then reaction mixture was filtered through celite and washed with HPLC grade MeOH. MeOH was driven out in a rotary evaporator and crude was dissolved in chloroform. Work up was done with brine water and dried. The residue upon chromatographic purification using 5% methanol in chloroform afforded 0.9g (81.8% yield) of pure *tert*-butyl-9-aminononanoate as a yellow liquid. ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 451 (calculated value for $C_{24}H_{39}O_5N_3 = 449.6$).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C15-NH₂, 14d

Yield: 90.5% ($R_f = 0.1$ in 5% methanol in chloroform).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C5F-NHBoc, 15a

HOBt (0.39g, 2.53mmol) and EDCI (0.48g, 2.53mmol) were sequentially added to an icecold stirred solution of Boc-Phe-OH (0.54g, 2.04mmol) in dry DCM. After half an hour N(ε)-Z-Lysine(-OMe)C5-NH₂ (1g, 2.54mmol) dissolved in dry DCM was added to the reaction mixture. DIPEA was added to make reaction mixtue slightly basic. The resulting solution was stirred at r.t. overnight. Then it was diluted with chloroform and washed sequentially with water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 2% methanol in chloroform afforded 0.9g (55.28% yield) of pure N(ε)-Z-Lysine(-OMe)C5F as a white gummy semi-solid. (R_f = 0.55 in 5% methanol in chloroform). ¹**H NMR** (300MHz, CDCl₃): δ = 1.3-1.4 [s, 9H], 1.5-1.7 [m, 6H], 2.15-2.35 [t, 2H], 2.9-3.1 [m, 4H], 3.2 [m, 2H], 3.75 [s, 3H], 4.25 [m, 1H], 4.6 [m, 1H], 5.0- [t, 1H], 5.1 [s, 2H], 5.4 [m, 1H], 6.5-6.65 [m, 1H], 7.05 [d, 1H], 7.15-7.4 [m, 10H]. **ESI-MS**: m/z = 641 (calculated value for C₃₄H₄₈O₈N₄ = 640.8).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C8F-NHBoc, 15b

Yield: 61% ($R_f = 0.6$ in 5% methanol in chloroform). ¹**H NMR** (200MHz, CDCl₃): $\delta = 1.1$ -1.8 [m, 25H], 2.1-2.2 [t, 2H], 2.9-3.2[m, 6H], 3.7 [s, 3H], 4.15-4.3 [m, 1H], 4.5-4.6 [m, 1H], 5.0-5.15 [m, 2H], 5.25-5.4 [m, 1H], 6.1-6.2 [m, 1H], 6.45-6.55 [m, 1H], 7.1-7.4 [m, 11H]. **ESI-MS**: m/z = 684 (calculated value for $C_{37}H_{54}O_8N_4 = 682.9$).

Synthesis of N(ε)-Z-Lysine(-OMe)C9F-NHBoc, 15c

Yield: 56.5% ($R_f = 0.6$ in 5% methanol in chloroform). ¹**H** NMR (300MHz, CDCl₃): $\delta = 1.1$ -1.9 [m, 27H], 2.15-2.25 [m, 2H], 2.95-3.3 [m, 6H], 3.65 [s, 3H], 4.2-4.3 [m, 1H], 4.55-4.65 [m, 1H], 5.1 [s, 2H], 5.3-5.4 [m, 1H], 5.9-6.0 [m, 1H], 6.5 [m, 1H], 7.15-7.4 [m, 11H]. **ESI-**MS: m/z = 697 (calculated value for $C_{38}H_{56}O_8N_4 = 696.9$).

Synthesis of N(ɛ)-Z-Lysine(-OMe)C15F-NHBoc, 15d

Yield: 61.8% ($R_f = 0.7$ in 5% methanol in chloroform).

Synthesis of N(ε)-Z-Lysine(-OMe)C5V, 15e

Yield: 65% ($R_f = 0.6$ in 5% methanol in chloroform). ¹**H NMR** (300MHz, CDCl₃): $\delta = 0.9$ -1.0 [d, 6H], 1.4 [s, 9H], 1.5-1.9 [m, 10H], 1.95-2.05 [m, 1H], 2.15-2.35 [m, 2H], 3.15-3.2 [m, 4H], 3.4-3.5 [m, 1H] 3.65 [s, 3H], 4.5-4.6 [m, 1H], 5.0 [m, 1H], 5.05 [s, 2H], 5.25 [d, 1H], 6.85 [m, 1H], 7.15 [m, 1H], 7.25-7.4 [s, 5H].

Synthesis of Lysine(-OMe)C5F, 16a

 $N(\varepsilon)$ -Z-Lysine(-OMe)C5F-NHBoc (0.8g, 1.25mmol) was dissolved in HPLC grade methanol. The air of the round bottom flask was chased by flushing nitrogen several times. 10% Pd on charcoal (0.5g) was added cautiously to the solution and inner walls of the flask were washed down with HPLC grade methanol. Again the air of the flask was chased by nitrogen flushing. Then hydrogen was passed through the reaction mixture and it was left stirring for overnight. Then it was filtered through celite and washed with HPLC grade methanol. The combined washings along with the filtrate was evaporated to afford 0.54g (85.1%) of Lysine(-OMe)C5F as a white semi solid. This was used directly in the next reaction without further purification. ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 507 (calculated value for C₂₆H₄₂O₆N₄ = 506.6).

Synthesis of Lysine(-OMe)C8F, 16b

Yield: 80% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 549 (calculated value for $C_{29}H_{48}O_6N_4 = 548.7$).

Synthesis of Lysine(-OMe)C9F, 16c

Yield: 88.5% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 563 (calculated value for $C_{30}H_{50}O_6N_4 = 562.7$).

Synthesis of Lysine(-OMe)C15F, 16d

Yield: 92.5% ($R_f = 0.1$ in 5% methanol in chloroform).

Synthesis of Lysine(-OMe)C5V, 16e

Yield: 78.1% ($R_f = 0.1$ in 5% methanol in chloroform). **ESI-MS**: m/z = 459 (calculated value for $C_{22}H_{42}O_6N_4 = 458.6$).

Synthesis of PRF-C5, 17a

HOBt (0.061 g, 0.33mmol) and HATU (0.15g, 0.39mmol) were sequentially added to an icecold stirred solution of RC5(-CO₂H) (0.27g , 0.9mmol) in dry DMF. After half an hour Lysine(-OMe)C5F (0.25g, 0.49mmol) dissolved in dry DMF was added to the reaction mixture. DIPEA was added drop wise to make reaction mixture slightly basic. The resulting solution was stirred at r.t. overnight. Then it was diluted with chloroform and washed sequentially with water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 2% methanol in chloroform afforded 0.33g (57.5% yield) of pure PRF-C5 as a reddish yellow gummy semi-solid. (R_f = 0.5 in 5% methanol in chloroform, v/v). ¹H NMR (300MHz, CDCl₃ + CD₃OD): δ = 0.7-0.8 [m, 2H] 1.1-1.2 [s, 9H], 1.2-1.7 [m, 16H], 2.0-2.2 [m, 4H], 2.9-3.1 [m, 4H], 3.3 [t, 4H], 3.6 [s, 3H, (merged with solvent peak)], 3.7 [m, 2H], 3.8-3.9 [m, 1H], 4.05-4.2 [m, 1H], 4.3-4.4 [m, 1H], 4.95-5.25 [m, 6H], 7.15-7.35 [m, 20H]. **ESI-MS**: m/z = 1164 (calculated value for C₆₁H₈₁O₁₄N₉ = 1163.4).

Synthesis of PRF-C8, 17b

Yield: 53.6% ($R_f = 0.6$ in 5% methanol in chloroform). ¹**H NMR** (200MHz, CDCl₃): $\delta = 1.1$ -1.4 [m, 33H], 1.4-1.9 [m, 8H], 2.05-2.15 [t, 2H], 2.15-2.25 [t, 2H], 2.75-3.3 [m, 8H], 3.7 [s, 3H], 3.75-3.9 [m, 2H], 3.95-4.1 [m, 1H], 4.25-4.35 [m, 1H], 4.55-5.65 [m, 1H], 4.95-5.3 [m, 6H], 5.7 [m, 1H], 5.95-6.0 [m, 1H], 6.3-6.35 [m, 1H], 6.6 [m, 1H], 7.15-7.45 [m, 20H]. **ESI-MS**: m/z = 1248 (calculated value for $C_{67}H_{93}O_{14}N_9 = 1248.1$).

Synthesis of PRF-C9, 17c

Yield: 61.2% ($R_f = 0.6$ in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃ + CD₃OD): $\delta = 1.2$ -1.7 [m, 41H], 2.1-2.3 [m, 6H], 3.0-3.2 [m, 4H], 3.3-3.35 [t, 4H], 3.7 [m, 3H], 3.85-4.0 [m, 2H], 5.0-5.3 [m, 6H], 7.15-7.45 [m, 20H]. **ESI-MS**: m/z = 1277 (calculated

value for $C_{69}H_{97}O_{14}N_9 = 1276.6$).

Synthesis of PRF-C15, 17d

Yield: 65.1% ($R_f = 0.7$ in 5% methanol in chloroform). ¹**H** NMR (200MHz, CDCl₃ + CD₃OD): $\delta = 1.1$ -1.4 [m, 20H], 1.5 [s, 9H], 1.5-1.85 [m, 10H], 2.15-2.25 [m, 4H], 2.3-3.0 [m, 4H], 3.75-4.4 [m, 4H], 5.0-5.4 [m, 6H], 6.2-6.3 [m, 2H], 6.5-6.6 [m, 2H], 7.25-7.45 [m, 20H].

Synthesis of PGV-C5, 17e

Yield: 54.5% ($R_f = 0.6$ in 5% methanol in chloroform). ¹H NMR (300MHz, CDCl₃ + CD₃OD): $\delta = 0.8-1.0$ [d, 6H], 1.45-1.55 [s, 9H], 1.55-2.0 [m, 15H], 2.1-2.3 [m, 4H], 3.15-3.3 [m, 6H], 3.65-3.8 [m, 6H], 4.4 [m, (merged with CD₃OD solvent peak), 1H], 5.1 [s, 2H], 7.25-7.4 [m, 5H]. **ESI-MS**: m/z = 749 (calculated value for $C_{37}H_{60}O_{10}N_6 = 748.9$).

Synthesis of PRR-C5, 17f

HATU (0.3g, 0.78mmol) was added to an ice-cold stirred solution of RC5(-CO₂H) (0.53g, 0.78mmol) in dry DMF. After half an hour L-lysine methyl ester di-hydrochloride (0.1g, 0.43mmol) dissolved in dry DMSO was added to the reaction mixture. Then drops of DIPEA were added till the reaction mixture was slightly alkaline. The reaction mixture was stirred at r.t. for 48 hours. Then it was diluted with chloroform and washed sequentially with 0.5N HCl, water and brine. The organic layer was dried and evaporated. The residue upon chromatographic purification using 1% methanol in chloroform afforded 0.38 g (60% yield) of pure PRR-C5 as a white solid. ($R_f = 0.7$ in 5% methanol in chloroform). ¹H NMR (200MHz, CDCl₃ + CD₃OD): $\delta = 1.3-1.4$ [m, 4H], 1.4-1.7 [m, 12H], 2.05-2.25 [m, 4H], 2.9-3.05 [m, 4H], 3.05-3.2 [m, 2H], 3.7 [s, 3H], 3.75-4.0 [m, 6H], 4.35-4.45 [m, 1H], 5.05-5.25 [m, 12H], 7.15-7.4 [m, 30H]. **ESI-MS**: m/z = 1472 (calculated value for $C_{77}H_{94}O_{10}N_6 = 1447.6$).

Synthesis of PFF-C5, 17g

Yield: 59.8% ($R_f = 0.6$ in 5% methanol in chloroform). ¹H NMR (400MHz, CDCl₃ + CD₃OD): $\delta = 1.3$ -1.4 [m, 4H], 1.45-1.85 [m, 6H], 2.1-2.3 [m, 4H], 2.75-3.15 [m, 10H], 3.7 [s, 3H], 4.25-4.3 [m, 3H], 4.95-5.1 [m, 4H], 7.15-7.35 [m, 20H]. ESI-MS: m/z = 944 [M+Na⁺] (calculated value for $C_{51}H_{64}O_{10}N_6 = 921.1$).

Synthesis of RF-C5, 18a

PRF-C5 (0.1g, 0.086mmol) was dissolved in TFA (2ml) under nitrogen atmosphere at 0^oC. Thioanisole (0.4ml, 3.4mmol) and TMS-OTf (0.6ml, 3.32mmol) were added sequentially to that cooled solution. The reaction mixture was allowed to come to r.t. and kept stirring for 24 hours. Then reaction was quenched with HPLC grade methanol. Methanol and excess TFA were chased by nitrogen flushing. The residue was dissolved in minimum amount of HPLC grade methanol and excess diethyl ether was added. A gummy yellowish liquid was precipitated. This was collected by centrifugation and re-precipitated from methanol-diethyl ether system repeatedly. Finally, upon chloride ion exchange chromatography (using amberlite IRA-400Cl chloride ion exchange resin) afforded 0.037g (65% yield) of pure RFC5 as a yellowish semi-solid. ($R_f = 0.1$ in 20% methanol in chloroform). **ESI-HRMS**: m/z = 662.4375 ([M+H]⁺, calculated value for $C_{32}H_{56}O_6N_9 = 662.4348$). RP-HPLC: Rt = 2.3 min (100% methanol), purity >99%.

Synthesis of RF-C8, 18b

Yield: 68.5% ($R_f = 0.1$ in 20% methanol in chloroform). **ESI-HRMS**: m/z = 746.5274 ($[M+H]^+$, calculated value for $C_{38}H_{68}O_6N_9 = 746.5292$). RP-HPLC: Rt = 3.8 min (100% methanol), purity >99%.

Synthesis of RF-C9, 18c

Yield: 72% ($R_f = 0.1$ in 20% methanol in chloroform). **ESI-HRMS**: m/z = 774.5579 ($[M]^+$, calculated value for $C_{40}H_{71}O_6N_9 = 774.5604$). RP-HPLC: Rt = 3.7 min (15% water in acetonitrile), purity >99%.

Synthesis of RF-C15, 18d

Yield: 74.3% ($R_f = 0.1$ in 20% methanol in chloroform). **ESI**: m/z = 943 ([M+H]⁺, calculated value for $C_{52}H_{96}O_6N_9 = 943.3$), 472 ([M+2H]²⁺, calculated 472.1). RP-HPLC: Rt = 3.87 min (100% methanol), purity >99%.

Synthesis of GV-C5, 18e

Yield: 60.5% ($R_f = 0.1$ in 10% methanol in chloroform). **ESI-HRMS**: m/z = 537.33955 ($[M+Na]^+$, calculated value for $C_{24}H_{46}O_6N_6Na = 537.3371$). RP-HPLC: Rt = 3.8 min (100% methanol), purity >99%.

Synthesis of RR-C5, 18f

Yield: 47% ($R_f = 0.0$, spot resided at baseline in 20% methanol in chloroform). **ESI-HRMS**: m/z = 336.2387 ([M+2H]²⁺, calculated value for [$C_{29}H_{60}O_6N_{12}$]/2 = 336.2334). RP-HPLC: Rt = 3.6 min (100% methanol), purity >99%.

Synthesis of FF-C5, 18g

Yield: 53% ($R_f = 0.1$ in 10% methanol in chloroform). **ESI-HRMS**: m/z = 653.4009 ([M+H]⁺, calculated value for $C_{35}H_{53}O_6N_6 = 653.4021$), 327.2064 ([M+2H]²⁺, calculated 327.2017). RP-HPLC: Rt = 3.9 min (100% methanol), purity >99%.

Synthesis of RF-C11, 18h

RF-C11 (n= 10) was synthesized according to previous work (Lee MJ et al., 2008). Yield: 60.8% ($R_f = 0.1$ in 20% methanol in chloroform). Final compound was characterized and verified by ESI-MS and purified by HPLC. ESI-MS: m/z = 831 ([M+H]⁺, calculated value for $C_{44}H_{80}O_6N_9 = 831.2$), 416 ([M+2H]⁺, calculated value for $C_{44}H_{80}O_6N_9 = 416.2$). RP-HPLC: Rt = 3.78 min (100% methanol), purity >98%.

Synthesis of RF-C5b

Synthesis of Boc-Protected Biotinylated Ethylenediamine, 19

First, 0.19 g HOBt (1.24 mmol), 0.23 g EDCI (1.20 mmol), and 0.20 g biotin (0.82 mmol) was added in 5 ml cold, dry DMF, followed by the addition of 0.20 g DMF solution of mono-BOC-ethylenediamine (1.25 mmol) and DIPEA dropwise. The resulting solution was stirred at r.t. for 16 h. Compound 19 was obtained through column chromatographic purification by using 4% methanol in chloroform (0.21 g 66.4% yield, Rf = 0.40 in 10% methanol in chloroform). ¹H NMR (300 MHz, CDCl3 + CD3OD): δ 1.3 [s, 2H], 1.42 [s, 9H], 1.50-1.75 [m, 4H], 2.2-2.4 [t, 2H], 2.7-3.0 [m, 2H], 3.15-3.4 [m, 5H], 4.25-4.4 [m, 2H].

Synthesis of $N(\epsilon)Z$ -lysine(-O-biotinylated ethylenediamine)-C5F, 21

Compound 15a was demethylated by using LiOH in THF:water:methanol (3:1:1) solvent mixture, yielding N(ϵ)Z-Lysine(OH)-C5F (90% yield, Rf = 0.250 in 5% methanol in chloroform). **ESI-MS**: m/z = 628 [M+H⁺] (calculated value for C₃₃H₄₇O₈N₄ = 627.7).

Compound 19 was subjected to BOC deprotection by using TFA, yielding biotinylated ethylenediamine (Compound **20**, 97.1% yield). Then 0.073 g HOBt (0.48 mmol), 0.091 g EDC (0.48 mmol), and 0.3 g N(ϵ)Z-Lysine(-OH)-C5F (0.48 mmol) were added in 3 ml cold,

dry DMF, followed by the addition of 0.57 g DMF solution of biotinylated ethylenediamine (0.57 mmol) and dropwise addition of DIPEA. The resulting solution was stirred at r.t. for overnight. After washing with 0.5 N HCl in brine solution and column chromatography by using 4% methanol in chloroform, compound 12 was obtained in pure form (0.256 g, 60%, Rf = 0.50 in 10% methanol in chloroform. ¹H NMR (500 MHz, CDCl3 + CD3OD): δ = 1.2-1.8 [m, 25H], 2.15-2.3 [m, 4H], 2.6 [d, 1H], 2.8-2.9 [m, 2H], 3.0-3.2 [m, 5H], 3.35 [m, 2H], 3.5-3.6 [m, 4H], 4.15-4.45 [m, 5H], 5.05 [s, 2H], 7.15-7.4 [m, 10H]. **ESI-MS**: m/z = 918 [M+Na⁺] (calculated value for C₄₅H₆₆O₉N₈SNa = 918.1).

Synthesis of Lysine(-O-biotinylatedethylenediamine)-C5F, 22

Compound 21 was subjected to Z-deprotection by using hydrogenolysis with 10% Pd on charcoal in methanol afforded Lysine(-O-biotinylated ethylenediamine)-C5F (78.8% yield). **ESI-MS**: $m/z = 762 [M+H^+]$ (calculated value for $C_{37}H_{60}O_7N_8S = 760.9$).

Synthesis of PRF-C5b, 23

Then 16 mg HOBt (0.1mmol), 40 mg HATU (0.1mmol), and 71 mg compound 12a (0.1 mmol) was added in 1 ml cold, dry DMF, followed by the addition of 0.13 g DMF solution of Lysine(-O-biotinylated ethylenediamine)-C5F (0.13 mmol) and the dropwise addition of DIPEA. The resulting solution was stirred at r.t. for overnight. Washing with 0.5 N HCl in brine solution and column chromatographic purification by using 5% methanol in chloroform yielded 0.074 g PRF-C5b in pure form (40% yield, Rf = 0.50 in 10% methanol in chloroform). ¹H NMR (500 MHz, CDCl3 + CD3OD): δ 1.1 [m, 2H], 1.2-1.7 [m, 31H], 2.05-2.3 [m, 6H], 2.6-2.7 [m, 1H], 3.4 [m, 4H], 3.5-3.6 [m, 1H], 3.8 [m, 1H], 3.9 [m,1H], 4.1-4.2 [m, 4H], 4.25-4.35 [m, 2H], 4.5 [m, 1H], 5.0-5.2 [m, 6H], 7.1-7.4 [m, 20H]. MALDI-MS: m/z = 1441 (calculated value for C₇₂H₉₉O₁₅N₁₃SNa = 1441.7)

Synthesis of RF-C5b, 24

PRF-C5b was deprotected and purified through selective precipitation by using methanol/acetone solvent mixture followed by 5% water in acetonitrile yielding pure RF-C5b (30% yield). **ESI-HRMS**: m/z 916.55272 ([M+H]⁺, calculated for C₄₃H₇₄O₇N₁₃S = 916.55494). RP-HPLC: Rt = 2.4 min (20% water in acetonitrile), purity >99%.

Fig1: HPLC profile of RF-C2 in 20% water in acetonitrile

Fig2: HPLC profile of RF-C3 in 20% water in acetonitrile

Fig3: HPLC profile of RF-C5 in 100% methanol

Fig4: HPLC profile of RF-C8 in 100% methanol

Fig5: HPLC profile of RF-C9 in 15% water in acetonitrile

Fig6: HPLC profile of RF-C11 in 100% methanol

Fig7: HPLC profile of RF-C15 in 100% methanol

Fig8: HPLC profile of GV-C5 in 100% methanol

Fig9: HPLC profile of RR-C5 in 100% methanol

Fig10: HPLC profile of FF-C5 in 100% methanol

Fig11: HPLC profile of RF-C5b in 20% water in acetonitrile

Fig. 12. MALDI-MS of compound 23

ESI-HRMS of compound RF-C5b (24)

ESI Reference

- Lee, M. J., Tasaki, T., Moroi, K., An, J. Y., Kimura, S., Davydov, I. V., and Kwon, Y. T. RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. *Proc. Natl. Acad. Sci.* U.S.A. 2005, **102**, 15030-15035.
- R. J. De Groot, T. Rumenapf, R. J. Kuhn, E. G. Strauss and J. H. Strauss. Sindbis virus RNA polymerase is degraded by the N-end rule pathway. *Proc. Natl . Acad. Sci. U.S.A.* 1991, 88, 8967-8971.
- 3. Y. Shirako and J. H. Strauss. Requirement for an Aromatic Amino Acid or Histidine at the N Terminus of Sindbis Virus RNA Polymerase. *J. Virol.* 1998, **72**, 2310-2315.
- Kwon, Y. T., Balogh, S. A., Davydov, I. V., Kashina, A. S., Yoon, J. K., Xie, Y., Gaur, A., Hyde, L., Denenberg, V. H., and Varshavsky, A. Altered activity, social behavior, and spatial memory in mice lacking the NTAN1p amidase and the asparagine branch of the N-end rule pathway. *Mol. Cell. Biol.* 2000, 20, 4135-4148.
- Kwon, Y. T., Lévy, F., and Varshavsky, A. Bivalent inhibitor of the N-end rule pathway. J. Biol. Chem. 1999, 274, 18135-18139.
- Tovchigrechko, A., and Vakser, I. A. GRAMM-X public web server for protein–protein docking. *Nucl. Acids Res.* 2006, 34, W310-W314.
- Stewart, J. J. Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements. *J. Mol. Model.* 2007, 13, 1173-1213.
- Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G. A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H. P., Izmaylov, A. F., Bloino, J., Zheng, G., Sonnenberg, J. L., Hada, M., Ehra, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Montgomery, Jr., J. A., Peralta, J. E., Ogliaro, F., Bearpark, M., Heyd, J. J., Brothers, E., Kudin, K. N., Staroverov, V. N., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A., Burant, J. C., Iyengar, S. S., Tomasi, J., Cossi, M., Rega, N., Millam, J. M., Klene, M., Knox, J. E., Cross, J. B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R. E., Yazyev, O., Austin, A. J., Cammi, R., Pomelli, C., Ochterski, J., Martin, R. L., Morokuma, K., Zakrzewski, V. G., Voth, G. A., Salvador, P., Dannenberg, J. J., Dapprich, S., Daniels, A. D., Farkas, O.,

Foresman, J. B., Ortiz, J. V., Cioslowski, J. and Fox, D. J. GAUSSIAN 09 (Revision A.2), Gaussian, Inc., Wallingford, CT, 2009

- 9. Sanner, M. F. A component-based software environment for visualizing large macromolecular assemblies. *Structure* 2005, **13**, 447-462.
- 10. Gasteiger, J., and Marsili, M. Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. *Tetrahedron* 1980, **36**, 3219-3228.
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., and Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 2009, **30**, 2785-2791.
- Dolinsky, T. J., Czodrowski, P., Li, H., Nielsen, J. E., Jensen, J. H., Klebe, G., and Baker, N. A. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. *Nucleic Acids Res.* 2007, **35**, W522-525.
- Wang, J., Cieplak, P., and Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? *J. Comput. Chem.* 2000, **21**, 1049-1074.
- Baker, N. A., Sept, D., Joseph, S., Holst, M. J., and McCammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. *Proc. Natl. Acad. Sci. U.S.A.* 2001, 98, 10037-10041.
- 15. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods* 1983, **65**, 55-63.

ESI Figure and Figure Legends

ESI Fig. S1

Fig. S1. The steady-state levels of various X-nsP4 model substrates of the N-end rule pathway were examined after 90 min of *in vitro* transcription/translation. Newly synthesized proteins were labeled with biotin-lysyl t-RNA. SDS-PAGE/WB using streptavidin-HRP conjugates. Note that DHFR-Ub-Pro-nsP4 was non-cleavable. *, nonspecific signal. These data complement Fig. 2F.

ESI Fig. S2

Fig. S2. The proteasome-mediated protein degradation through the N-end rule pathway. Met-, Arg-, Cys-, and Phe-GFP proteins were transiently expressed in HeLa cells. A proteasome inhibitor, MG132 (20 μ M), was incubated for 4 hr before cell harvest. Samples were resolved by SDS-PAGE, and anti-GFP antibodies were used for subsequent immunoblotting. actin, loading control.

Fig. S3. (A) Heterovalent RF-C5 inhibits the proteolysis of type 1 N-end rule substrate ArgnsP4 better than dipeptides or heterovalent inhibitors with different tether lengths. The effect of synthesized compounds and dipeptides on Arg-nsP4 degradation was monitored using a time-course Western blot for biotin. Arg-nsP4. DHFR-Ub-Arg-nsP4 fusion proteins were expressed in rabbit reticulocyte lysates. They were cotranslationally cleaved by deubiquitylating enzymes (DUBs) at the Ub-Arg junction yielding a long-lived DHFR-Ub reference and an Arg-nsP4 substrate that is short-lived because Arg is a destabilizing residue of the N-end rule pathway. (B) Same as (A) except using the type 2 model substrate, Tyr-nsP4. Time indicate the reaction time of *in vitro* degradation assays in the presence of heterovalent inhibitors.

Fig. S4. A and B, same as Supplementary Figs. S3A and S3B, respectively, except the Odyssey system was used instead of a typical WB and various monovalent controls for RF-C5 were used as indicated. Time indicates the total reaction time. These data complement Fig. 4A.

Fig. S5. Heterovalent inhibitors showed higher stability against endopeptidases than dipeptides. The effect of 150 μ M bestatin, an endopeptidase inhibitor, on the efficacies of Arg-Ala and Phe-Ala dipeptides were compared with that of RF-C5. Proteins were expressed for 60 min and samples were subject to SDS-PAGE/western blotting using streptavidin-HRP. These data complement Fig. 4D.

ESI Fig. S6

Fig. S6. Heterovalent inhibitors delayed degradation of transiently overexpressed RGS4. Twenty-four hours after cotransfecting MEFs with RGS4 and LacZ plasmids, cells were incubated with 10, 50, or 100 μ M RF-C11 or Arg-Ala dipeptides in the presence or absence of serum. RGS4 was strongly stabilized by 10 μ M MG132 and more inhibitory effects of heterovalent inhibitors were observed in the serum-free condition.

Fig. S7. Pulse-chase analysis of RGS4, a physiological N-end rule substrate, using heterovalent inhibitors showed delayed degradation of newly synthesized RGS4 protein in MEFs. Transfected cells were preincubated with 100 μ M RF-C11 or GV-C11, labeled for 12 min with ³⁵S-Met/Cys, followed by anti-RGS4 immunoprecipitation, SDS-PAGE analysis, and autoradiography.